ストックスクリーナーアプリを入手
1.51
0.00%
0.00
前日終値:
$1.51
開ける：
$1.52
24時間の取引高:
893.79K
Relative Volume:
0.96
時価総額：
$75.01M
収益：
$300.00K
当期純損益:
$-27.61M
株価収益率:
-2.6138
EPS:
-0.5777
ネットキャッシュフロー:
$-22.17M
1週間 パフォーマンス:
-10.12%
1か月 パフォーマンス:
-11.18%
6か月 パフォーマンス:
-44.07%
1年 パフォーマンス:
+83.03%
1日の値動き範囲:
$1.43
$1.53
1週間の範囲:
$1.43
$1.74
52週間の値動き範囲:
$0.5562
$3.82
iBio Inc Stock (IBIO) Company Profile
Compare IBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.51 | 75.01M | 300.00K | -27.61M | -22.17M | -0.5777 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Oppenheimer | Outperform |
| 2025-10-17 | 開始されました | Leerink Partners | Outperform |
| 2024-05-28 | 開始されました | Chardan Capital Markets | Buy |
| 2021-11-29 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-01-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-06-26 | 開始されました | Alliance Global Partners | Buy |
すべてを表示
iBio Inc (IBIO) 最新ニュース
We Think iBio (NASDAQ:IBIO) Can Afford To Drive Business Growth - Sahm
Price to sales forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO) - The Globe and Mail
IBIO Maintained by Chardan Capital -- Price Target Stays at $5.0 - GuruFocus
IBIO News | IBIO INC (NASDAQ:IBIO) - ChartMill
IBIOiBio Inc Latest SEC Filings - Finviz
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - Moomoo
$IBIO stock is up 13% today. Here's what we see in our data. - Quiver Quantitative
iBio’s IBIO-610 Antibody Achieves 98% Activin E Inhibition and Boosts Fat Loss in Obese Primates, Outperforming Semaglutide Alone 1 - Minichart
iBio Highlights Promising New Preclinical Obesity Antibody Data - TipRanks
Innovative Findings on IBIO-610 from iBio - GuruFocus
iBio (NASDAQ: IBIO) obesity antibody cuts Activin E and spares lean mass - Stock Titan
iBio Inc. announced research results showing that a single administration of the candidate drug IBIO-610 in an obese non-human primate model achieved nearly complete inhibition of active activin E for up to eight weeks. - Bitget
iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study - The Manila Times
iBio drug held Activin E down for 8 weeks in obese primates - Stock Titan
IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Value Benchmark Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell 3000E Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell Microcap Index - marketscreener.com
IBio, Inc.(NasdaqCM: IBIO) added to Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to revenue forward of iBio, Inc. – NASDAQ:IBIO - TradingView
Price to book forward of iBio, Inc. – NASDAQ:IBIO - TradingView
How iBio aims to stand out in obesity by targeting ‘both sides of the equation’ for antibody discovery - Fierce Biotech
iBio, Inc. Actuals & Estimates (NASDAQ:IBIO) - TradingView
0JV0 Forecast — Price Target — Prediction for 2027 - TradingView
IBIO Forecast — Price Target — Prediction for 2027 - TradingView
iBio Inc. (IBIO) Slips 1.23% — Stock Tests Support Zone Amid Low VolumeTrend Reversal Picks - dars.gov.et
iBio Inc. Q1 2026 Earnings: EPS Beat Mitigates Broader Market ConcernsProfit Inflection Point - dars.gov.et
iBio Inc (IBIO) Institutional Confidence - TradingKey
Top iBio (IBIO) Competitors 2026 - MarketBeat
iBio Inc (IBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
iBio Inc (IBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
iBio Inc (IBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
iBio Inc (IBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
iBio Inc (IBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
iBio Inc (IBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
iBio Inc (IBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
iBio Inc (IBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
IBIO Q1 2026 Earnings: EPS Miss Amidst Continued R&D InvestmentAdjusted Earnings Analysis - dars.gov.et
Raymond James Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $5 - 富途牛牛
iBio Inc. (IBIO) Edges Higher as Biotech Sector Shows Cautious OptimismBollinger Expansion - newsline.com
Could iBio (IBIO) Be an Underrated Obesity Stock? - Insider Monkey
5 Under-the-Radar AI Stocks to Buy in 2026 - Insider Monkey
iBio Inc. (IBIO) Nears Key Support Amid Slight Decline: Technical AnalysisQuote Data - newsline.com
IBIO Initiates Coverage On Raymond James -- Rating Set to Outper - GuruFocus
IBIO Initiates Coverage On Raymond James -- Rating Set to Outperform - GuruFocus
Raymond James initiates iBio stock coverage with outperform rating By Investing.com - Investing.com South Africa
Raymond James initiates iBio stock coverage with outperform rating - Investing.com
iBio Q1 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentAnalyst Earnings Estimate - dars.gov.et
iBio Inc. (IBIO) Q1 2026 Earnings: EPS Misses Estimates as Biotech Firm Reports No RevenueEarnings Growth Forecast - newsline.com
B. Riley Initiates IBio at Buy With $6 Price Target - Moomoo
IBIO: Advancing antibody-based therapies for obesity, muscle preservation, and weight maintenance - TradingView
iBio Inc (IBIO) 財務データ
収益
当期純利益
現金流量
EPS
iBio Inc (IBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Duran Felipe | Chief Financial Officer |
Mar 19 '26 |
Buy |
2.02 |
24,835 |
50,132 |
35,974 |
| Brenner Martin | See Remarks |
Mar 19 '26 |
Buy |
2.02 |
12,336 |
24,919 |
30,652 |
2.64%
大文字化:
|
ボリューム (24 時間):